NL - ProFibrix closes $11m Series A financing round
ProFibrix BV, a Leiden-based biotech company focused on products to stop bleeding and initiate tissue repair, has closed a Series A financing round raising $11m. The round was led by Index Ventures and backed by some of the current share holders of ProFibrix. It was also announced that Dr. Bram Bout, who previously held the position of VP protein production at Crucell and has approximately 15 years experience in the biopharmaceutical industry, has joined ProFibrix as of 1 April 2007 as chief technology officer.
More on Early-stage
Swisscom leads CHF 20m series-A for Anybiotics
Equity Pitcher and Ace & Company are also investing in the autonomous industrial robot developer
Vidici Ventures et al. in €2m seed round for ReceiptHero
Startup will use the proceeds for further product development, and to expand into Sweden and the Baltic region next year
Alfvén & Didrikson leads $12m round for Klevu
Retail search engine startup has raised €15m since being founded in 2013
Sofinnova, Polaris lead CHF 54m series-A for Noema
Noema plans to use the fresh capital to fund the development of its clinical-stage pipeline
Latest News
Nazca exits Moldcom to Cranemere's ES Group
This is the first divestment made by Nazca IV, a €275m vehicle raised by the GP in 2016
Hg-backed IT Relation bolts on Improsec
With the latest acquisition, IT Relation will add cybersecurity as its fourth business area, alongside cloud services, business consultancy and professional services
Mutares-backed Balcke-Dürr sells Rothemühle to trade
Industrial energy efficiency equipment producer sold its Poland-based operations in April 2020
Horizon's Timico buys Arcus Cloud Services
Horizon bought a majority stake in Timico in 2016 via a deal valuing the company at more than £50m